𝔖 Bobbio Scriptorium

✦ LIBER ✦

Seven years of tamoxifen no better than 5 years among women with estrogen receptor-positive breast cancer and negative axillary nodes

✍ Scribed by Kaija Holli

Book ID: 114483832
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 76 KB
Volume: 3
Category: Article
ISSN: 1363-4054
DOI: 10.1054/ebon.2001.0176

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A cost-effectiveness analysis of axillar

A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor–positive breast cancer and clinically negative axillary nodes

✍ Richard K. Orr; Nananda F. Col; Karen M. Kuntz 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Active smoking and the risk of estrogen

Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years

✍ Kawai, Masaaki (author);Malone, Kathleen E. (author);Tang, Mei Tzu C. (author);L 📂 Article 📅 2014 🏛 John Wiley and Sons Inc 🌐 English ⚖ 106 KB

Active smoking and the risk of estrogen

Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years

✍ Kawai, Masaaki (author);Malone, Kathleen E. (author);Tang, Mei Tzu C. (author);L 📂 Article 📅 2014 🏛 John Wiley and Sons Inc 🌐 English ⚖ 106 KB

Doxorubicin and cyclophosphamide adjuvan

Doxorubicin and cyclophosphamide adjuvant chemotherapy is no more effective than cyclophosphamide, methotrexate, and 5-fluorouracil for premenopausal axillary lymph node positive breast cancer: There is no clear evidence that HER-2 status affects the relative effects of doxorubicin and cyclophosphamide vs cyclophosphamide, methotrexate and 5-fluorouracil in women with operable breast cancer

✍ Dino Amadori 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 346 KB

Five versus more than five years of tamo

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors: Fisher B, Dignam J, Bryant J, DeCillis A, Wickeham L, Wolmark N, Constantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux R, Shibata H, Terz A, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickney HL J Natl Cancer Inst 1996:88:1529-42

📂 Article 📅 1997 🏛 Elsevier Science 🌐 French ⚖ 115 KB